A groundbreaking clinical trial is underway, as scientists have successfully used prime editing to directly alter DNA within a human body. This significant development, reported by Nature on October 22, 2026, represents a potential leap forward in treating genetic disorders, including those affecting the liver and nervous system.
The experimental treatment focuses on Wilson disease, a rare inherited condition where the body struggles to eliminate excess copper, leading to its accumulation and damage to organs like the liver and brain. Unlike traditional gene-editing methods that often require cells to be modified outside the body before reintroduction, this trial employs an in vivo approach, making targeted genetic changes directly inside the patient.
What is Prime Editing?
Prime editing is an advanced form of CRISPR gene editing. It allows researchers to make precise, targeted changes to DNA, including rewriting specific genetic code, inserting new sequences, or deleting unwanted ones. This technique offers greater flexibility compared to conventional CRISPR-Cas9 methods, which typically cut DNA to disable a gene. Prime editing's ability to rewrite DNA sequences is particularly valuable for correcting specific mutations responsible for inherited diseases that simpler methods cannot address.
Targeting Wilson Disease
Wilson disease is caused by mutations in the ATP7B gene, which is crucial for producing a protein that helps transport excess copper out of the liver. When this process fails, copper builds up, causing severe damage. Current treatments involve medications to remove or limit copper accumulation, often requiring complex, long-term regimens.
By attempting to correct the underlying genetic defect, prime editing aims to offer a more durable solution. However, the long-term efficacy and lasting benefits of this experimental therapy will need to be established through ongoing clinical trials.
The Significance of In-Body Editing
The key innovation of this trial is the direct editing of DNA inside the patient's body. This in vivo gene editing approach could potentially streamline the manufacturing and administration of genetic treatments, making them faster and more accessible. Previous prime editing trials, such as one for a rare immune disorder, involved modifying blood stem cells outside the body before reinfusion. In contrast, the Wilson disease trial directly targets liver cells within the patient.
US biotechnology company Prime Medicine initiated the trial, treating its first participant in October 2026. Initial results are anticipated in 2027.
Risks and Future Outlook
While promising, direct in vivo gene editing presents considerable challenges. Researchers must ensure the editing machinery reaches the correct cells, makes the intended genetic changes accurately, and avoids any harmful alterations elsewhere in the genome. The long-term safety and effectiveness also require thorough assessment; a successful initial treatment does not guarantee widespread applicability.
As of the Nature report, no gene-editing therapy had yet received approval for direct in vivo use. The outcome of this trial will provide critical evidence for the potential translation of prime editing into practical treatments for various genetic diseases. The release of initial results in 2027 will be a major milestone, helping to determine the treatment's safety, its ability to modify the targeted gene, and its impact on patient condition.